How much does a box of Apelis cost in 2024?

Apelix, an innovative drug, has shown significant efficacy in treating certain types of breast cancer. It is mainly used to treat advanced or metastatic breast cancer that is hormone receptor positive, human epidermal growth factor receptor2 negative, and carries PIK3CA gene mutations. This type of breast cancer is clinically common and difficult to treat, and the emergence of Apelvis has brought new hope to patients.

Apelix blocks the growth and spread of cancer cells by inhibiting the activity of the PI3K signaling pathway. The PI3K signaling pathway plays a key role in the occurrence and development of breast cancer, and PIK3CA gene mutations can lead to abnormal activation of this pathway. Apelvis can precisely act on this target, exert anti-tumor effects, help patients control disease progression and prolong survival.

In addition to directly inhibiting cancer cell growth, Apelvis also exhibits good synergy with other drugs. For example, when used in combination with fulvestrant, it can further enhance the therapeutic effect and improve the progression-free survival of patients. This combination treatment has achieved impressive results in clinical trials and is recommended as the first-choice second-line treatment for breast cancer.

However, Apelvis is not suitable for all breast cancer patients. Its efficacy is mainly concentrated in patients carrying PIK3CA gene mutations, so it may not be effective in other types of breast cancer. Therefore, before using Apelvis, doctors will conduct genetic testing to ensure that patients will benefit from treatment.

Overall, apelvis, as a breast cancer treatment drug targeting specific gene mutations, provides a new treatment option for patients with advanced or metastatic breast cancer and brings greater hope for survival.